Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset

Download Results

Project # Sort descending	Project Title	Research Focus Area	Research Program	Administering IC	Institution(s)	Investigator(s)	Location(s)	Year Awarded
3R01AT010742-01S1	Examining Trauma Prevalence and Exploring Interoception as a Mechanism of Emotion Regulation in MOUD	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NCCIH	UNIVERSITY OF WASHINGTON	PRICE, CYNTHIA J; MERRILL, JOSEPH O	Seattle, WA	2022
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-107; PA-21-071 Summary: Effective treatments for opioid use disorder need to address the complex needs of patients, which may include mental health problems and substantial chronic pain. This project will measure lifetime trauma experienced by men and women who take medication for opioid use disorder, as well analyze the association between types of trauma and symptomatic distress. The project will also explore whether an individual’s perceptions of sensations from inside their body (interoceptive awareness) affect emotional control and mental health. This research will fill knowledge gaps i critical to better understanding opioid use disorder treatment and relapse.
3R01AT010757-02S1	The study of Gpr149 in nociception and the peripheral action of minor cannabinoids	Preclinical and Translational Research in Pain Management	Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain	NCCIH	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	HELLMAN, JUDITH	San Francisco, CA	2020
NOFO Title: Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome NOFO Number: NOT-TR-20-008 Summary: The cannabis plant contains many active compounds known collectively as cannabinoids that have been shown to possess analgesic and anti-inflammatory properties. These compounds exert their biological activity, in part, through the cannabinoid receptor. The cannabinoid receptor is a member of a class of proteins known as G-protein coupled receptors (GPCRs). This study will test whether a GPCR with unknown biological function, called Gpr149, has a role in the activity of cannabinoids. The study will identify and characterize Gpr149 expression in mouse cells, and deeply characterize the action of minor cannabinoids, endocannabinoids and products of inflammation to modulate Gpr149. This research will provide insight into the analgesic and anti-inflammatory action of minor cannabinoids and into the role of Gpr149 in nociception and the sensitization of nociceptors to inflammatory mediators.
3R01AT010773-02S1	Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics	Preclinical and Translational Research in Pain Management	Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain	NCCIH	RESEARCH TRIANGLE INSTITUTE	WILEY, JENNY L.	Research Triangle Park, NC	2020
NOFO Title: Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome NOFO Number: NOT-TR-20-008 Summary: G-protein coupled receptor 3 (GPR3) is an orphan receptor present in the central nervous system (CNS) that plays important role in many normal physiological functions and is involved in a variety of pathological conditions. Although the brain chemical that activates this receptor has not been identified, work with GPR3 knockout mice has identified GPR3 as a novel drug target for several Central Nervous System (CNS) mediated diseases including neuropathic pain. However, despite the emerging behavioral implications of the GPR3 system, little is known about how GPR3 affects behavior due to the lack of potent and selective chemical probes that allow scientists to examine functioning of the receptor. Recently, two cannabinoid chemicals present in the cannabis plant were discovered as affecting GPR3. This study will modify the chemical structure of these compounds to increase their potency and selectivity so that they may be used as pharmacological tools to investigate the role of GPR3 in modulating pain. In addition, this project focuses on identifying new compounds that show promise for development into therapeutics for the treatment of pain.
3R01DA001411-45S2	Monitoring the Future: Drug Use and Lifestyles of American Youth	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	University of Michigan at Ann Arbor	Miech, Richard A.	Ann Arbor, MI	2019
NOFO Title: Research Project Grant (Parent R01) NOFO Number: PA-13-302
3R01DA037621-05S1	Long-term activation of spinal opioid analgesia after imflammation - Supplement	Preclinical and Translational Research in Pain Management	Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain	NIDA	University of Pittsburgh	TAYLOR, BRADLEY K	Pittsburgh, PA	2019
NOFO Title: Administrative Supplements for Validation of Novel Non-Addictive Pain Targets (Clinical Trials Not Allowed) NOFO Number: NOT-NS-18-073 Summary: Severe tissue injury generates central sensitization. Latent sensitization (LS) is a silent form of central sensitization that persists after tissue has healed and overt signs of hyperalgesia have resolved. Pain remission during LS is likely maintained by tonic opioid receptor activity. The opioid receptor inverse agonist, naloxone, can reinstate experimental pain when delivered one week after the resolution of secondary hyperalgesia following first degree thermal injury. Our aims are to test: 1) the hypothesis that burn or surgery triggers LS and long-term opioid analgesia in humans; 2) the hypothesis that mu-opioid receptor (MOR) constitutive activity (MORCA) receptors by opioid peptides maintains endogenous analgesia and restricts LS to a state of pain remission; 3) the extent to which MORs inhibit neural activity in the DH and synaptic strength in presynaptic terminals of primary afferent nociceptors during LS; and 4) whether MORs inhibit spinal NMDA receptor subunits to block pain during LS.
3R01DA041434-03S1	IMPROVING ACCESS TO SUBSTANCE ABUSE EVIDENCE-BASED PRACTICES FOR YOUTH IN THE JUSTICE SYSTEM: STRATEGIES USED BY JPOS	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	Oregon Social Learning Center, Inc.	SHEIDOW, ASHLI J	Eugene, OR	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: Justice-involved young adults are one of the highest-risk populations for the development of opioid use disorder (OUD) and other significant public health problems, but they usually lack access to evidence-based practices that could potentially prevent this trajectory. The risk of unintentional death and other deleterious outcomes and long-term costs for opioid misuse for young adults, their communities and society (costs estimated at more than $115 billion annually) make this a priority, with rural areas in need of the most attention and assistance. The overriding purpose of the proposed pilot study is to prevent the onset of OUD by improving young adult offenders’ access to evidence-based risk reduction interventions, like contingency management (CM), by testing whether officers in the adult probation and parole setting can deliver such an intervention to their young adult substance using probationers who have not yet developed OUD. The primary motivation for this pilot is the clear public health need for improving and expanding delivery of substance use risk reduction interventions for young adults in the justice system. The ultimate outcome would be prevention of OUD in this high-risk population.
3R01DA042059-04S2	THE SAFETY AND IMPACT OF EXPANDED ACCESS TO NALOXONE IN HEALTH SYSTEMS	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	Kaiser Foundation Research Institute	BINSWNGER, INGRID A	Oakland, CA	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591
3R01DA042859-02S1	OPIOIDS: PREVENTION OF IATROGENIC OPIOID DEPENDENCE AFTER SURGERY	New Strategies to Prevent and Treat Opioid Addiction		NIDA	University of Michigan, Ann Arbor	WALJEE, JENNIFER FILIP	ANN ARBOR, MI	2018
NOFO Title: NIH Research Project Grant (Parent R01) NOFO Number: PA-16-160 Summary: Morbidity and mortality related to prescription opioids are accelerating in the United States. Identifying the factors that lead to new opioid dependence among opioid naïve patients is a critical opportunity to reduce prescription opioid dependence and unintended diversion. In the United States, the majority of individuals who become opioid dependent receive their first opioid prescription following surgical procedures, yet there are no clinical guidelines to inform appropriate postoperative opioid use. We will examine the patient factors that are associated with postoperative pain and opioid consumption among a cohort of patients undergoing common elective abdominal procedures. We will identify the provider characteristics in postoperative opioid prescribing practices, and design and implement a provider-directed intervention to optimize postoperative opioid prescribing. Findings will inform patients and providers regarding the risk of opioid dependence following surgery, and will establish a patient-centered data infrastructure that yields continuous feedback to providers regarding appropriate opioid prescribing practices.
3R01DA043122-03S1	HEALTH AND JUSTICE: A CONTINUUM OF CARE FOR HIV AND SU FOR JUSTICE-INVOLVED YOUTH	Translation of Research to Practice for the Treatment of Opioid Addiction		NIDA	NEW YORK STATE PSYCHIATRIC INSTITUTE	ELKINGTON, KATHERINE S	New York, NY	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: Overcoming barriers to substance use (SU) screening and enrollment in SU care is central to decreasing justice-involved youth’s (JIY) negative HIV-related outcomes. This project proposes to embed HIV testing outreach workers from a youth-focused medical and HIV treatment program into an alternative sentencing program (ASP) to deliver a new service delivery model (Link2CARE) that integrates evidenced-based protocols for JIY to promote HIV and sexually transmitted infection (STI) testing and HIV and SU risk screening, and provide on-site intervention and cross-system linkage to HIV, STI, and SU care. We propose to determine the efficacy of Link2CARE delivered by health staff embedded within the ASP on HIV, STI, and SU outcomes; to determine the influence of theoretically based intervention mechanisms of change on the proposed HIV and SU outcomes; and to describe Link2CARE implementation and elucidate the system/organizational-, staff-, and youth-level factors that influence implementation of Link2CARE in an ASP.
3R01DA043476-01A1S1	BUPRENORPHINE FOR PROBATIONERS AND PAROLEES: BRIDGING THE GAP INTO TREATMENT	Translation of Research to Practice for the Treatment of Opioid Addiction	Justice Community Opioid Innovation Network (JCOIN)	NIDA	FRIENDS RESEARCH INSTITUTE, INC.	GORDON, MICHAEL SCOTT	Baltimore, MD	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: A large number of probationers/parolees with opioid use disorder have limited access to effective treatment. This study is the first random clinical trial in the United States that will assess the effectiveness of buprenorphine treatment using MedicaSafe, a system composed of secure pre-packaged buprenorphine/naloxone cartridges, designed to be dispensed by a SmartKey device that enables clinicians to track patient adherence. The study will initiate treatment at a community corrections office compared to referral to a community program. The public health impact of the proposed study would be widespread, as this model of care could be implemented throughout many areas of the United States with high rates of opioid use disorder in their probation/parolee populations that lack access to methadone treatment.
3R01DA043476-02S1	BUPRENORPHINE FOR PROBATIONERS AND PAROLEES: BRIDGING THE GAP INTO TREATMENT	Translation of Research to Practice for the Treatment of Opioid Addiction	Justice Community Opioid Innovation Network (JCOIN)	NIDA	FRIENDS RESEARCH INSTITUTE, INC.	Gordon, Michael Scott	Baltimore, MD	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: A large number of probationers/parolees with opioid use disorder have limited access to effective treatment. This study is the first random clinical trial in the United States that will assess the effectiveness of buprenorphine treatment using MedicaSafe, a system composed of secure pre-packaged buprenorphine/naloxone cartridges, designed to be dispensed by a SmartKey device that enables clinicians to track patient adherence. The study will initiate treatment at a community corrections office compared to referral to a community program. The public health impact of the proposed study would be widespread, as this model of care could be implemented throughout many areas of the United States with high rates of opioid use disorder in their probation/parolee populations that lack access to methadone treatment.
3R01DA044015-02S1	SUPPLEMENTAL APPLICATION FOR CLINICAL AND GENETIC RISK PROFILE OF OPIOID USE DISORDER	New Strategies to Prevent and Treat Opioid Addiction		NIDA	Geisinger Clinic	TROIANI, VANESSA; BERRETTINI, WADE H; ROBISHAW, JANET D	DANVILLE, PA	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: This project is focused on identifying the clinical, genetic, and neural characteristics that convey risk for prescription opioid addiction. We will leverage the central biorepository and electronic health record (EHR) database of the Geisinger Health System to conduct large-scale genomics research and phenotype development. Through a collaboration with Regeneron Pharmaceuticals, the Geisinger biobank currently contains DNA samples on about 110,000 participants and includes both Illumina OmniExpressExome genotyping and whole exome sequence data, including common and rare variants, from over 60,000 of these subjects. This discovery cohort contains thousands of chronic musculoskeletal pain patients who have been taking greater than 120 mg equivalents of morphine for more than three months. Using EHR and self-report tools to develop a case definition and quantitative scoring, we will derive a clinical/genetic profile of prescription opioid addiction. This profile will be enhanced via integration of neuroimaging data.
3R01DA044184-02S1	DEVELOPMENT & MALLEABILITY FROM CHILDHOOD TO ADULTHOOD	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	Johns Hopkins University	IALONGO, NICHOLAS S	Baltimore, MD	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: The Family School Partnership (FSP) and classroom-centered (CC) interventions targeted aggressive-coercive behavior and poor academic achievement as antecedents of the distal outcomes of antisocial behavior, substance abuse/dependence, psychiatric symptoms/disorders, high-risk sexual behavior and successful adaptation to the relevant developmental demands of the educational, work, romantic relationships and family (both family of procreation and origin/orientation) social fields/contexts. The participants of the FSP and CC original prevention trial were a population (n = 798) of urban, predominately African-American young adults, who began first grade in the fall of 1993 in nine elementary schools in predominantly low- to lower-middle-income Baltimore areas. The central purpose of the proposed study is to extend through ages 31-35 an examination of normal and pathogenic development and the impact of these two universal first-grade preventive interventions on the distal targets mentioned above. We will continue to study the role of phenotypic and genetic factors (and their interactions) as well as the impact of the interventions on the development and course of substance use/abuse/dependence, psychiatric symptoms/disorders, antisocial behavior/disorder and high-risk sexual behavior through young adulthood. The knowledge accrued over the course of the proposed assessments should serve to inform the nature, targets and timing of our future preventive intervention efforts.
3R01DA044522-16S1	PROXIMAL AND DISTAL PATHWAYS TO YOUNG ADULT OPIOID MISUSE	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	University of Washington	OESTERLE, SABRINA	Seattle, WA	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591
3R01DA044745-01A1S1	FACILITATING SUSTAINMENT THROUGH IMPLEMENTATION FEEDBACK: THE SIC COACHING MODEL	New Strategies to Prevent and Treat Opioid Addiction		NIDA	Oregon Social Learning Center, Inc.	SALDANA, LISA	Eugene, OR	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: This proposal aims to test the impact of an empirically derived implementation strategy—under real-world conditions and across multiple child service systems—on successful adoption and sustainment of two evidence-based programs that address adolescent substance abuse: Treatment Foster Care Oregon (TFCO; formerly Multidimensional Treatment Foster Care) and Multidimensional Family Therapy (MDFT). The overarching goal of this proposal is to evaluate whether the integration of implementation fidelity (fidelity to the implementation process) with intervention fidelity (fidelity to the clinical intervention) can increase the probability that a new organizational site not only successfully adopts a program but develops the infrastructure to ensure it can sustain. This study will (a) evaluate the effect of stages of implementation completion coaching strategy (SIC-CS) on outcomes of program adoption and sustainment, (b) extend the SIC to include measurement of sustainment, and (c) examine cost and resource patterns most likely to yield sustainable programs.
3R01DA044778-02S1	EXTENSION OF RISK FOR PRESCRIPTION OPIOID MISUSE IN ADOLESCENTS WITH THE FULL AGE SPECTRUM OF ADOLESCENCE THROUGH EMERGING ADULTHOOD	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	Oregon Health & Science University	Feldstein Ewing, Sarah W.; Wilson, Anna Camille (contact)	Portland, OR	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: Current rates of prescription opioid misuse are rising to epidemic levels among adults. These rates may be even higher among adolescents and young adults (AYAs), who have elevated levels of substance exploration and misuse during this precise developmental period. AYAs who are exposed to opioids via legitimate prescriptions by age 18 are at increased risk for misuse after high school. However, there is a substantial gap in our knowledge of what factors might contribute to the development of misuse and related poor outcomes in these high-risk youth. Identifying factors that convey risk for increasing opioid use and problematic use would inform AYA models of opioid abuse and inform the development of preventive interventions to modify risk in medical settings, which are a unique point of entry into opioid use, and a key setting in which to examine AYA outcomes. We will use a developmental model of the impact of opioid exposure by legitimate prescription during late adolescence, with consideration for pain and psychological characteristics of the individual within the psychosocial (family, peer, educational and work context). Determining mechanisms and moderators of risk during this developmental transition will provide critical information for the design of interventions aimed at reducing opioid use disorders in at-risk AYA.
3R01DA045396-02S1	Brief Individual and Parent Interventions for Marijuana Misuse in Truant Adolescents	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	Brown University	SPIRITO, ANTHONY	Providence, RI	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: Four out of five youth in the juvenile justice (JJ) system show evidence of being under the influence during their offenses, and more than half test positive for substances at the time of their arrest. Preventive intervention approaches that can be easily implemented within JJ settings may offer greater access to substance use care as well as increase families’ motivation to comply with court referrals to seek further services. It is especially important to evaluate interventions for court-involved, non-incarcerated (CINI) juveniles, as these youth account for two-thirds of those arrested; however, the bulk of extant research has been conducted with detained or incarcerated youth. In this application for supplemental funding, we capitalize on our parent grant (Brief Individual and Parent Interventions for Marijuana Misuse in Truant Adolescents) by proposing to develop an adjunctive, targeted preventive intervention for marijuana-using, JJ youth who are at elevated risk for illicit opioid use. The goal will be to develop a protocol for a single-session, parent-adolescent preventive intervention to decrease the likelihood of illicit opioid use in CINI adolescents. This formative work will culminate in a draft intervention manual.
3R01DA045745-02S1	Intervention to Increase Naloxone Engagement and Distribution in Community Pharmacies: A Four-State Randomized Trial	Translation of Research to Practice for the Treatment of Opioid Addiction	Justice Community Opioid Innovation Network (JCOIN)	NIDA	BOSTON MEDICAL CENTER	Green, Traci C	Boston, MA	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: Expanding access to naloxone in the community through the pharmacy can be a critical mechanism for extending this lifesaving medication’s reach. This study will partner with two large retail pharmacy chains and integrate two interventions that provide knowledge and training for pharmacists to identify and effectively engage with patients who may be at high risk for an opioid overdose. The interventions will be combined into a cohesive educational program, implemented in 160 community pharmacies and tested for effectiveness. Study findings will create a generalizable, evidence-based training and toolkit for pharmacists caring for patients who use prescribed or illicit opioids, in more than 40 states adopting or expanding pharmacy naloxone.
3R01DA045872-01A1S1	Examining the synergistic effects of cannabis and prescription opioid policies on chronic pain, opioid prescribing and opioid poisoning	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	New York University School of Medicine	Cerda, Magdalena; Martins, Silvia Saboia	New York, NY	2019
NOFO Title: Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R01) NOFO Number: PA-17-135 Summary: As states make unprecedented changes to prescription opioid (PO) policies and cannabis laws, the independent and synergistic contributions that both types of measures have on opioid-prescribing practices and opioid overdoses, with and without benzodiazepines (BZDs), are not known. This study will pursue this aim in the U.S. population and Medicaid patients with chronic pain, aiming to: (1) examine whether nonmedical use of POs, BZDs, and heroin and opioid- and BZD-use disorders decreased following enactment of more restrictive PO policies and less restrictive cannabis laws in 2004–2019; and (2) test whether Medicaid patients are less likely to have claims for opioid prescribing, clinic visits for chronic pain, and opioid overdoses following enactment of more restrictive PO policies and less restrictive cannabis laws in 2001–2019. This study will provide findings about the types of policies that are most likely to end the opioid epidemic.
3R01DA046527-02S1	RESEARCHING EFFECTIVE STRATEGIES TO PREVENT OPIOID DEATH (RESPOND)	New Strategies to Prevent and Treat Opioid Addiction	Preventing Opioid Use Disorder	NIDA	Boston Medical Center	LINAS, BENJAMIN P	Boston, MA	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591
3R01DA051067-01S1	Treatment of Co-Occurring Opioid Use Disorder with Alcohol, Other Drug, and/or Mental Disorders: The Role of Innovative Models and Integrated Care	New Strategies to Prevent and Treat Opioid Addiction	Optimizing Care for People with Opioid Use Disorder and Mental Health Conditions	NIDA	BRANDEIS UNIVERSITY	REIF, SHARON	Waltham, MA;	2020
NOFO Title: Notice of Special Interest: HEAL Supplements to Improve the Treatment and Management of Common Co-occurring Conditions and Suicide Risk in People Affected by the Opioid Crisis NOFO Number: NOT-MH-20-025 Summary: People with opioid use disorders (OUD) have high rates of co-occurring alcohol, stimulant and other drug disorders, as well as mental disorders. Traditionally, treatment for OUD has been ?siloed? even though these high rates of co-occurring conditions emphasize the need for comprehensive treatment to address holistic needs. As the opioid crisis continues, attention to the whole person and access to comprehensive mental health and substance use treatment as well as primary care is needed. This study aims to better understand co-occurring mental health disorders, alcohol use disorders, and/or other substance use disorders among people with OUD, in the context of innovative integrated care networks for people with OUD. This study examines how innovative OUD treatment models work for individuals with co-occurring mental health and substance use by 1) assessing mental health treatment quality measures and outcomes; 2) testing how these innovative treatment models compare to other OUD treatment for people who have OUD and other substance use disorders; and 3) considering the ways people with OUD access co-occurring disorder care. The findings from this study will provide needed information to improve mental health, alcohol, and other substance use treatment for individuals with OUD, whether or not they are in OUD treatment and may provide information to help move the system from siloed efforts to truly integrated care
3R01DA057605-01S1	Diversity Supplement - Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY)	Cross-Cutting Research	Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research	NIDA	UNIVERSITY OF KENTUCKY	SLAVOVA, SVETLA STEFANOVA (contact); TALBERT, JEFFERY C	Lexington, KY	2023
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-107 Summary: RADOR-KY is a near real-time, state-wide surveillance system to monitor prevention and treatment services for opioid use disorder (OUD). This project will fill gaps in this system by capturing data from agencies receiving state funding to provide treatment and support services for people with OUD. Access to the additional data will help expand and improve surveillance dashboards being used to coordinate and target resources for preventing overdose deaths.
3R01DA057630-01S1	Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services	Cross-Cutting Research	Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research	NIDA	UNIVERSITY OF CALIFORNIA LOS ANGELES	SHOVER, CHELSEA LEIGH (contact); GOODMAN, DAVID	Los Angeles, CA	2023
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: PA-21-071 Summary: The International Classification of Diseases 10th revision codes are insufficient to accurately identify individuals who use opioids and stimulants together. This project will search already collected electronic health record data using a computer program to identify people with polysubstance use and determine what health care they receive. The research will improve understanding of polysubstance use in a region of Los Angeles, California, with very high rates of overdoses involving fentanyl and stimulants.
3R01DE029187-01S2	LIGHT and Lymphotoxin targeting for the treatment of chronic orofacial pain conditions	Preclinical and Translational Research in Pain Management	Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain	NINDS	UNIVERSITY OF TEXAS HLTH SCIENCE CENTER	AKOPIAN, ARMEN N; RUPAREL, SHIVANI B; TUMANOV, ALEXEI V	San Antonio, TX	2020
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-023 Summary: Chronic orofacial pain during Temporomandibular Disorders (TMD) and oral cancer is a significant health problem with scarce non-opioid treatment options. This study aims to validate critical regulators of the balance between protective immunity and immunopathology during chronic inflammatory diseases?tumor necrosis factor alpha superfamily members, LIGHT (TNFSF14) and lymphotoxin-beta (LT?) and their receptors, LT?R and Herpes Virus Entry Mediator (HVEM)?as novel therapeutic targets. The study also seeks to determine whether inhibition of LIGHT and LT? signaling prevents the development and inhibits maintenance of chronic TMD and oral cancer pain via peripheral mechanisms involving plasticity of immune, muscle and tumor cells as well as sensory neurons. The study will define the contribution of LIGHT and LT? signaling to TMD-induced excitability of trigeminal sensory neurons innervating the masseter muscle and joint. New validated therapeutic targets for prevention and treatment of orofacial pain that can be peripherally targeted would reduce side effects of current pain medicates related to drug dependence or tolerance.
3R01DE029202-01S2	Validation of Blocking TSP4/Cava2d1 Interaction as a New Target for Neuropathic Pain	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDCR	UNIVERSITY OF CALIFORNIA-IRVINE	LUO, ZHIGANG DAVID	Irvine, CA	2022
NOFO Title: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem NOFO Number: NOT-OD-22-033 Summary: This research provides support to strengthen data management, data sharing, and data readiness efforts within the HEAL Initiative. This support further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. It also provides an opportunity for existing HEAL Initiative award recipients to increase data “FAIR”-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets.